Ajanta Pharma mentioned it has signed an in-licensing settlement with Biocon to market semaglutide, a GLP-1 receptor agonist, throughout 26 nations spanning Africa, the Center East and Central Asia, as Indian drugmakers sharpen their concentrate on advanced diabetes therapies in rising markets.
Underneath the settlement, Biocon will provide semaglutide to Ajanta for unique advertising in 23 nations and semi-exclusive advertising in three nations, the corporate mentioned in a regulatory submitting.
Launch deliberate publish patent expiry, approvals awaited
Semaglutide is used to enhance glycaemic management in adults. The product patent is about to run out in many of the goal markets in March 2026, clearing the best way for branded generic launches.
Ajanta mentioned it plans to commercialise the drug after receiving regulatory approvals, that are anticipated in late 2026 or early 2027.
Ajanta bets on branded generics playbook
The Mumbai-based drugmaker has constructed a powerful branded generics enterprise with its personal area pressure throughout greater than 30 nations, notably in Africa, South-East Asia, Central Asia and the Center East.
The corporate operates throughout a number of therapeutic segments, together with cardiology, anti-diabetic, ophthalmology and common well being, and presently markets over 220 manufacturers in rising markets, supported by a area pressure of greater than 2,000 medical representatives, in line with the corporate.
Administration commentary
“GLP-1 therapies have seen speedy international acceptance and have emerged as blockbuster merchandise worldwide,” Yogesh Agrawal, managing director of Ajanta Pharma, mentioned, including that the corporate goals to scale semaglutide right into a high-growth model in markets the place it has a powerful on-ground presence.
Biocon chief govt Siddharth Mittal mentioned the partnership would assist develop the worldwide footprint of Biocon’s GLP-1 portfolio and enhance entry to semaglutide in rising markets by way of Ajanta’s industrial attain.
Monetary snapshot
For FY25, Ajanta Pharma reported income of Rs 4,648 crore, EBITDA of Rs 1,260 crore and revenue after tax of Rs 920 crore, with a three-year income CAGR of 11% and PAT CAGR of 25%, the corporate mentioned.
Ajanta Pharma share value
Ajanta Pharma’s share value has jumped almost 4% in early commerce. The inventory is up over 10.43% within the final 1 month. Nonetheless, it’s down over 7.58 % in 2025 to date.
Leave a Reply